Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

@article{Copland2006DasatinibT,
  title={Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.},
  author={M. Copland and A. Hamilton and L. Elrick and J. Baird and E. Allan and N. Jordanides and M. Barow and J. Mountford and T. Holyoake},
  journal={Blood},
  year={2006},
  volume={107 11},
  pages={
          4532-9
        }
}
Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and inhibits the majority of kinase mutations in IM-resistant chronic myeloid leukemia (CML). We have previously demonstrated that IM reversibly blocks proliferation but does not induce apoptosis of primitive CML cells. Here, we have attempted to overcome this resistance with dasatinib. Primitive IM-resistant CML cells showed only single-copy BCR-ABL but expressed… Expand
632 Citations
Proteasome inhibition in chronic myeloid leukaemia
  • Highly Influenced
  • PDF
Novel drug combinations for the eradication of Ph+/BCR-ABL+ haemopoietic stem cells in chronic myeloid leukaemia
  • PDF
Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells
  • 13
  • Highly Influenced
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
  • 898
  • PDF
...
1
2
3
4
5
...